89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. The company was founded in 2018 and is headquartered in San Francisco, California. Show more

Location: 655 Montgomery Street, San Francisco, CA, 94111, United States | Website: https://www.89bio.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

1.301B

52 Wk Range

$4.16 - $11.84

Previous Close

$8.77

Open

$8.84

Volume

1,300,412

Day Range

$8.72 - $9.24

Enterprise Value

777.1M

Cash

561.2M

Avg Qtr Burn

-109.8M

Insider Ownership

0.55%

Institutional Own.

Qtr Updated

06/30/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Pegozafermin (BIO89-100) (FGF21 analog) Details metabolic dysfunction-associated steatohepatitis	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Pegozafermin (BIO89-100) (FGF21 analog) Details Severe hypertriglyceridemia	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Pegozafermin (BIO89-100) (FGF21 analog) Details Non-alcoholic steatohepatitis	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.